These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 7923319)

  • 1. Outcomes research and modeling therapeutic interventions for economic evaluations.
    Langley PC
    Clin Ther; 1994; 16(3):538-52. PubMed ID: 7923319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research.
    Kozma CM; Reeder CE; Schulz RM
    Clin Ther; 1993; 15(6):1121-32; discussion 1120. PubMed ID: 8111809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit and cost-effectiveness analysis of drug therapy.
    Dao TD
    Am J Hosp Pharm; 1985 Apr; 42(4):791-802. PubMed ID: 3925768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.
    Westerlund T; Marklund B
    J Clin Pharm Ther; 2009 Jun; 34(3):319-27. PubMed ID: 19646078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for the economic evaluation of lipid studies in health systems.
    Langley PC
    Value Health; 1998 Nov; 1(4):208-11. PubMed ID: 16674540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of cost-consequence modeling in outcomes research.
    Stergachis A
    Pharmacotherapy; 1995; 15(5 Pt 2):40S-42S. PubMed ID: 8577629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting feasibility and acceptability of a practice-based educational intervention to support evidence-based prescribing: a qualitative study.
    Watkins C; Timm A; Gooberman-Hill R; Harvey I; Haines A; Donovan J
    Fam Pract; 2004 Dec; 21(6):661-9. PubMed ID: 15528289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In search of the evidentiary foundation of published Canadian economic evaluations (2001-06).
    Tarride JE; Lim ME; Bowen JM; McCarron CE; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
    Int J Technol Assess Health Care; 2009 Apr; 25(2):214-21. PubMed ID: 19331712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal.
    Soto J
    Int J Technol Assess Health Care; 2002; 18(1):94-111. PubMed ID: 11987445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.